ICMR Advances First-in-Human Trials for Blood Cancers, Flu, and Zika Vaccine
ICMR's Clinical Trials Initiative for Blood Cancers, Flu, and Zika
The Indian Council of Medical Research (ICMR) has announced a groundbreaking initiative to advance first-in-human clinical trials for vaccines targeting Zika and seasonal flu along with therapies for blood cancers.
Collaborative Efforts and Partnerships
- The ICMR has formalized agreements with multiple partners including Aurigene Oncology for multiple myeloma treatment.
- Indian Immunologicals is involved in developing a Zika vaccine.
- A collaborative trial for a seasonal flu vaccine is underway with Mynvax Private.
- A pact with ImmunoACT focuses on CAR-T cell therapy for chronic lymphocytic leukemia.
As stated by the Ministry of Health, this initiative is crucial for establishing India as a leader in pharmaceutical development. Union Health Minister J P Nadda emphasized its importance in providing affordable healthcare solutions.
Impact on India's Health Landscape
The initiative aims to enhance India's clinical research capacity by developing indigenous solutions and ensuring affordable healthcare for all citizens.
The network of phase 1 clinical trials includes key institutions across India, supported by a central coordinating unit at ICMR Headquarters in New Delhi. This effort positions India as a hub for healthcare innovation.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.